ORIGINAL ARTICLE

The Effect of Ropinirole on the Quality of Life in Patients with Restless Legs Syndrome in Korea: An 8-Week, Multicenter, Prospective Study

Yong Won Cho, a,i, Seung Bong Hong, b,i, Do Hyung Kim, a,i, Ho Won Lee, c,i, Eun Yeon Joo, c,i, Jee Hyun Kim, d,i, Won Chul Shin, e,i, Kee Hyung Park, f,i, Sun Jung Han, g,i, Hyang Woon Lee h,i

a Department of Neurology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
b Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
c Department of Neurology, Kyungpook National University School of Medicine, Daegu, Korea
d Department of Neurology, Dankook University Medical College, Cheonan, Korea
e Department of Neurology, Kyung Hee University School of Medicine, Seoul, Korea
f Department of Neurology, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea
g Department of Neurology, Inam Neuroscience Research Center, Sanbon Medical Center, Wonkwang University, Gunpo, Korea
h Department of Neurology, Ewha Womans University School of Medicine and Ewha Medical Research Institute, Seoul, Korea
i Korean Sleep Research Society, Seoul, Korea

Received March 11, 2012
Revised May 29, 2012
Accepted May 29, 2012

Correspondence
Yong Won Cho, MD
Department of Neurology, Dongsan Medical Center, Keimyung University School of Medicine, 680 Gukchaebosang-ro, Jung-gu, Daegu 700-842, Korea
Tel +82-53-420-5786
Fax +82-53-422-4265
E-mail neurocho@dsmc.or.kr

Correspondence
Ho Won Lee, MD
Department of Neurology, Kyungpook National University School of Medicine, 680 Gukchaebosang-ro, Jung-gu, Daegu 700-712, Korea
Tel +82-53-250-7831
Fax +82-53-250-7840
E-mail neuromd@knu.ac.kr

*Two first authors contributed equally to this work.

Background and Purpose  Dopamine agonists are first-line drugs for treating the symptoms of restless legs syndrome (RLS). However, few studies have investigated the effect of dopamine agonists on the quality of life (QoL) in RLS patients. We conducted a study to determine whether ropinirole exerts positive effects on the QoL in RLS patients and to analyze the underlying factors.

Methods  Primary RLS patients from eight medical centers were recruited in the study. They were evaluated in the baseline phase using various questionnaires including the Korean versions of the International Restless Legs Scale (K-IRLS), RLS QoL questionnaire (K-RLSQoL), and the Short Form 36 Health Survey (SF-36). After taking ropinirole for 8 weeks the same questionnaires were again completed as a re-evaluation. We analyzed the statistical difference using a paired t-test, a Pearson’s correlation, and a stepwise multiple regression in order to identify the factors associated with the QoL change.

Results  A total of 107 subjects, including 65 (60.7%) females, completed this study. They were aged 51.68 ± 14.80 years (mean ± SD) and had a symptom duration of 8.8 ± 9.0 months. After treatment with ropinirole, there were significant improvements on the K-RLSQoL, SF-36, and K-IRLS. The Pearson’s correlation analysis showed that the improvement of QoL in RLS patients was significantly correlated with the severity of RLS (r=0.236, p<0.014) at baseline.

Conclusions  The results from this study suggest that treatment with ropinirole can improve the QoL in RLS patients. The improvement in the QoL is more related with the improvement of RLS symptoms.

Key Words  restless legs syndrome, dopamine agonists, quality of life, sleep.

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2013 Korean Neurological Association 51
Ropinirole Effects on Quality of Life in RLS Patients

Introduction

Restless legs syndrome (RLS) is a chronic sensorimotor neurological disorder1-5 with a reported prevalence of 3.9-11.5% in the general population.6,7 It is characterized by leg discomfort with nocturnal aggravation, and the symptom severity aggravates with age.8,9 Therefore, RLS patients commonly complain of both sleep disturbance and somatic symptoms. Due to these clinical characteristics the quality of life (QoL) of RLS patients is worse than that of healthy controls, and even worse than that of patients with chronic medical diseases, such as hypertension and type 2 diabetes.10-13

L-dopa has been prescribed for RLS symptoms since Akpanir reported the effects of L-dopa in RLS.14 However, its strong association with the augmentation of RLS symptoms,15 Thus, there has been an interest in the use of dopamine agonists for RLS patients. Ergot-derived dopamine agonists such as pergolide and cabergoline have been shown to improve RLS symptoms,16 but they have potential risks of fibrotic side effects with cardiac valvulopathy.17 The non-ergot-derived dopamine agonists ropinirole and pramipexole are not associated with such complications, which have made them the first-line treatment of RLS.18

Ropinirole exhibits a high affinity for D2 and D3 receptors, and controls nigrostriatal and mesolimbic-mesocortical dopaminergic activity.19 Clinical trials have shown that ropinirole significantly improves symptoms of RLS,19-21 producing scores on the mean International Restless Legs Scale (IRLS) that are 29-37% lower than those in placebo groups, and reducing periodic limb movements during sleep relative to baseline or placebo.22 Furthermore, ropinirole significantly improved the QoL in RLS patients compared to placebos. However, the effects on the QoL in RLS patients have not been fully elucidated, and all of these studies were performed only in Western countries.14-21

The purpose of this study was to elucidate the effect of ropinirole on the QoL in Korean patients with RLS and the underlying factors.

Methods

This was a multicenter, national trial lasting 8 weeks that was conducted in eight university hospitals in Korea. We enrolled all consecutive primary RLS patients over 18 years old who consented to participate in the study. RLS was diagnosed by neurologists based on diagnostic standards set by the National Institutes of Health workshop on RLS during face-to-face interviews using the validated Korean-language version of the John Hopkins Telephone Diagnostic Questionnaire.1,22 After excluding any mimic diseases through a direct physical examination and laboratory tests, the remaining patients were diagnosed with RLS. All patients had a score of at least 15 on the Korean version of the IRLS (K-IRLS) at baseline.23 We excluded other comorbid sleep disorders through analysis of sleep questionnaires, comorbidities to RLS, or secondary RLS caused by pregnancy or by other diseases such as chronic kidney disease, peripheral polyneuropathy, and iron-deficiency anemia. However, subjects with only peripheral iron deficiency without definite cause were included.

Patients received ropinirole once daily at 2 hours before bedtime, with treatment starting at a dose of 0.25 mg. The dose was then titrated upwards over 4 weeks until they were judged to have reached their optimal dose or until they were receiving the maximum dosage (4.0 mg/day). Down-titration was allowed during the titration period if patients experienced adverse events. Patients were maintained on a constant dose of ropinirole from weeks 4 to 8. We assessed adverse effects of ropinirole and regularly checked blood pressure, heart rate, and vital signs whenever they visited a clinic.

QoL was evaluated based on two questionnaires: the Korean version of the RLS QoL questionnaire (K-RLSQoL) and the Short Form 36 Health Survey (SF-36).24 The K-RLSQoL is a validated translated version of the RLS QoL questionnaire. Scores are from 0 to 100 points, with a lower score indicating a worse QoL. The SF-36 health questionnaire is currently a widely used tool to assess health-related QoL that also has been validated.24 It comprises eight domains: physical function, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores are from 0 to 100 points, with a lower score indicating a worse QoL. The symptom severity was measured using the K-IRLS.23 We also evaluated the sleep quality and mood based on the Korean version of the Pittsburg Sleep Quality Index (PSQI-K),24 the Insomnia Severity Index, the Korean version of the Epworth Sleepiness Scale,26 the Hospital Anxiety Scale,27 and the Beck Depression Inventory-2 (BDI-2),28 in addition to the demographic variables. Most of the questionnaires used in this study underwent a validation process involving Korean populations, and they were completed at baseline and at week 8. The patients were divided into two groups, responders and nonresponders, based on whether or not the K-IRLS score had decreased at week 8, respectively. During the survey, research coordinators who received training were available to help subjects who experienced difficulty completing the questionnaires. The study was approved by the institutional ethics committee at each university hospital.

Statistical analysis

Continuous and categorical variables are presented as mean±SD and frequency values, respectively. The significance of the
QoL and other scale changes between the baseline and after treatment were analyzed using the paired t-test. Correlations between QoL score changes and related factors, such as age, age at symptom onset, symptom duration, RLS severity, sleep quality, insomnia severity, and depression, were assessed using Pearson’s correlation. Stepwise multiple regression analysis was used to select the significant predictors for the QoL changes in RLS patients, and at each step independent variables were entered if there were factors significantly correlated with the QoL. Differences in QoL changes between the baseline and after treatment were tested by analysis of covariance using baseline scores as covariates. Statistical analyses were performed using the statistical software package SPSS

Table 1. Demographic and clinical characteristics of the restless legs syndrome (RLS) patients

| Characteristic                  | Value [n=107] |
|--------------------------------|--------------|
| Age (years)                    | 51.68±14.80  |
| Gender (female), % (n)         | 60.7 [65]    |
| BMI (kg/m²)                    | 23.80±2.98   |
| History of alcohol consumption, % (n) | 33.6 [36]    |
| PSQI-K                         | 10.6±4.4     |
| BDI-2                          | 12.4±8.6     |
| Duration of symptoms (years)   | 8.8±9.0      |
| Symptom severity (K-IRLS)      | 23.4±7.5     |
| Mild (n=6, 5.6%)                |              |
| Moderate (n=31, 29.0%)         |              |
| Severe (n=50, 46.7%)           |              |
| Very severe (n=20, 18.7%)      |              |
| Total SF-36                    | 63.0±19.9    |
| K-RLSQoL                       | 64.5±17.9    |

Data are mean±SD values except where stated otherwise.

BDI-2: Beck Depression Inventory-2, BMI: body mass index, K-IRLS: Korean version of the International Restless Legs Scale, K-RLSQoL: Korean version of the restless legs syndrome quality of life questionnaire, PSQI-K: Korean version of the Pittsburg Sleep Quality Index.

One hundred and seven RLS patients were enrolled: their age was 51.68±14.80 years (range 19-75 years), and 65 (60.7%) were female. The demographic and clinical characteristics of RLS patients are listed in Table 1. The score for RLS symptom severity was 23.4±7.5, and the duration of symptoms was 8.8±9.0 years. The distribution of RLS symptom severity was as follows: 6 (5.6%) mild, 31 (29.0%) moderate, 50 (46.7%) severe, and 20 (18.7%) very severe; age and sex did not differ significantly between these four subgroups. The baseline QoL scores were 64.5±17.9 for K-RLSQoL and 63.0±19.9 for total SF-36 (Table 1).

All patients received ropinirole for 4 weeks and maintained a stable dosage for the following 4 weeks. The QoL of RLS patients was significantly improved after 8 weeks of ropinirole treatment, as measured by the K-RLSQoL (73.7±18.4 p<0.001) and total SF-36 (67.5±19.8, p=0.004) scores. The individual domains of the SF-36 indicated significant differences between baseline and after treatment in bodily pain (52.8±23.5 vs. 63.6±23.8, p=0.001), general health (48.6±20.6 vs. 51.8±21.0, p=0.025), vitality (48.7±20.0 vs. 53.6±17.9, p=0.008), physical domain (57.7±20.3 vs. 63.2±20.5, p=0.001), and mental domain (62.7±19.2 vs. 65.8±18.1, p=0.041) (Fig. 1, Table 2). The K-IRLS score was significantly lower after ropinirole treatment (16.8±7.9) than the baseline 23.4±7.5, p<0.001). The scores on the sleep-related scales were also improved from baseline to after treatment: PSQI-K (10.6±4.4 vs. 9.2±4.4, p≤0.001), Insomnia Severity Index (14.5±7.1 vs. 10.5±6.5, p≤0.001), and Korean version of the Epworth Sleepiness Scale (7.2±3.9 vs. 6.1±3.9, p=0.007); however, the
score on the Depression Scale (BDI-2) did not differ after treatment (Fig. 2, Table 2). The daily dose of ropinirole at 8 weeks was 0.62±0.43 mg.

The patients were divided into two groups based on the efficacy of ropinirole (responders: n=86, 80%; nonresponders: n=21, 20%) to determine whether the improved QoL was purely associated with the change in symptom severity or with other treatment effects. The responders showed greater improvements (p<0.05) on all subscales except general health, vitality, and mental domain than nonresponders (Table 3).

The improvement of QoL in RLS patients was significantly correlated with the severity of RLS (r=0.236, p=0.014) at baseline. A stepwise multiple regression for factors affecting the K-RLSQoL score change was performed using the following independent factors: age, gender, age at symptom onset, symptom duration, depression (BDI-2), RLS severity (K-IRLS score), sleep quality (PSQI-K score), and total SF-36. The severity of symptoms was found to be significantly associated with the change in K-RLSQoL scores (β=0.586, p=0.017), with RLS patients with more severe RLS symptoms showing greater improvement in QoL after ropinirole treatment.

Adverse events were reported in nine patients (8.3%): dizziness (n=5, 4.6%), nausea (n=1, 0.9%), dry mouth (n=1, 0.9%), fatigue (n=1, 0.9%), and leg edema (n=1, 0.9%). Most of these adverse events were mild to moderate in intensity, and did not cause any patient to withdraw from the study.

**Discussion**

This study found improvement in the QoL as well as an improved symptom severity after short-term ropinirole treatment. The QoL was improved in terms of both physical and mental health. The QoL of patients with RLS is known to be considerably worse than that in healthy controls, and similar to that in patients with chronic medical diseases such as diabetes and Parkinson’s disease.1,1,20 Thus, the positive effect of ropinirole found in the present study represents further evidence that it is effective in the treatment of RLS. Ropinirole was generally tolerated well and there were no reported serious adverse events in our study.

The ropinirole-induced changes in the SF-36 scores for bodily pain, general health, and vitality domains indicated that patients using ropinirole experienced improvements in their bodily pain and general health, and had more energy and less fatigue. In particular, the responders showed greater improvements in most domains of the SF-36. The improvement of QoL in RLS patients was assessed using both the disease-specific K-RLSQoL and the SF-36. This finding that ropinirole improved the QoL of RLS patients was similar to that of a previous study.19 The data presented here support the notion that treatment with ropinirole can lead to improvement in QoL in RLS patients. However, another study found that ropinirole was associated with a greater improvement in QoL when this was assessed using the disease-specific measure (i.e., RLS QoL questionnaire) than with generic measures (SF-36).18 Western studies have produced different findings for QoL after ropinirole treatment when using the SF-36, which could be due to

**Table 2. Clinical characteristics at baseline and after 8 weeks of ropinirole treatment**

|                      | Baseline | After treatment | p   |
|----------------------|----------|-----------------|-----|
| K-RLSQoL             | 64.5±17.9| 73.7±18.4       | <0.001|
| Total SF-36          | 63.0±19.9| 67.5±19.8       | 0.004|
| SF36_PF             | 75.4±23.8| 77.3±23.8       | 0.255|
| SF36_RP             | 64.2±41.0| 70.8±40.6       | 0.053|
| SF36_BP             | 52.4±25.3| 63.6±23.8       | <0.001|
| SF36_GH             | 48.6±20.6| 51.8±21.0       | 0.025|
| SF36_V              | 48.7±20.0| 53.6±17.9       | 0.008|
| SF36_SF             | 74.2±24.5| 78.0±23.1       | 0.070|
| SF36_RE             | 77.3±37.7| 79.1±37.6       | 0.635|
| SF36_MH             | 64.0±21.0| 66.6±16.1       | 0.196|
| PH                  | 57.7±20.3| 63.2±20.5       | <0.001|
| MH                  | 62.7±19.2| 65.8±18.1       | 0.041|
| K-IRLS              | 23.4±7.5 | 16.8±7.9        | <0.001|
| BDI-2               | 12.4±8.6 | 11.5±10.1       | 0.191|
| PSQI_K              | 10.6±4.4 | 9.2±4.4         | <0.001|
| ISI                 | 14.5±7.1 | 10.5±6.5        | <0.001|
| KESS                | 7.2±3.9  | 6.1±3.9         | 0.007|

Data are means±SD values.

BDI-2: Beck Depression Inventory-2, ISI: Insomnia Severity Index, K-IRLS: Korean version of the International Restless Legs Scale, K-RLSQoL: Korean version of the restless legs syndrome quality of life questionnaire, KESS: Korean version of the Epworth Sleepiness Scale, MH: mental domains, PH: physical domains, PSQI-K: Korean version of the Pittsburg Sleep Quality Index, SF36: Short Form 36 Health Survey, SF36_BP: bodily pain, SF36_GH: general health, SF36_PF: physical function, SF36_MH: mental health, SF36_RE: role limitations due to emotional problems, SF36_RP: role limitations due to physical problems, SF36_SF: social functioning, SF36_V: vitality.
Table 3. Changes in quality of life in responder and nonresponder groups

|                      | Baseline | After treatment | p     |
|----------------------|----------|----------------|--------|
|                      | Nonresponders | Responders | Nonresponders | Responders |     |
| K-RLSQoL             | 69.9±15.5 | 63.2±18.3 | 61.1±3.3 | 76.7±1.6 | <0.001 |
| Total SF36           | 66.2±21.8 | 62.2±19.5 | 56.0±2.9 | 70.3±1.4 | <0.001 |
| SF36_PF             | 79.8±20.8 | 74.4±24.5 | 66.7±3.4 | 79.9±1.7 | 0.001 |
| SF36_RP             | 73.8±40.7 | 61.8±40.9 | 48.4±6.5 | 76.3±3.2 | <0.001 |
| SF36_BP             | 60.2±26.4 | 50.5±24.8 | 47.2±4.3 | 67.7±2.1 | <0.001 |
| SF36_GH             | 50.0±20.5 | 48.3±20.7 | 49.6±3.0 | 52.3±1.5 | 0.427 |
| SF36_V              | 51.4±17.6 | 48.0±20.5 | 51.1±3.4 | 54.2±1.7 | 0.410 |
| SF36_SF             | 73.4±30.4 | 74.5±23.1 | 67.3±4.0 | 80.7±2.0 | 0.003 |
| SF36_RE             | 74.7±39.3 | 78.3±37.5 | 58.9±6.2 | 84.1±3.1 | <0.001 |
| SF36_MH             | 64.0±25.0 | 64.1±20.0 | 62.9±3.2 | 67.5±1.6 | 0.196 |
| PH                  | 62.9±20.5 | 56.3±20.2 | 51.8±2.9 | 66.0±1.4 | <0.001 |
| MH                  | 63.2±21.1 | 62.6±18.8 | 57.8±2.9 | 67.9±1.4 | 0.003 |

Baseline data are mean±SD (standard deviation) values, after-treatment data are mean±SE (standard error) values. K-RLSQoL: Korean version of the restless legs syndrome quality of life questionnaire; MH: mental domains; PH: physical domains; SF36: Short Form 36 Health Survey; SF36_BP: bodily pain; SF36_GH: general health; SF36_MH: mental health; SF36_PF: physical function; SF36_RE: role limitations due to emotional problems; SF36_RP: role limitations due to physical problems; SF36_SF: social functioning; SF36_V: vitality.

This instrument not fully covering aspects of sleep in RLS patients.

RLS patients complain of both leg discomfort and sleep problems. Ropinirole effectively treats the symptoms of RLS as measured by the K-IRLS, improving sleep quality and reducing both sleep disturbance and daytime somnolence. These positive effects of ropinirole on sleep were similar to those found in previous studies, and should prove beneficial in the management of RLS. However, the improvement of QoL in RLS patients is due to alleviating symptoms of RLS rather than improving sleep quality.

The mean ropinirole daily dosage was 0.62 mg, which is smaller than that found in Western studies (1.5-1.9 mg). It seems that the symptoms of Korean RLS patients responded well to low-dosage ropinirole. The mean K-IRLS score in the present study was 23 at baseline and 17 after 8 weeks of ropinirole administration, while the mean adjusted change in IRLS scores between baseline and week 12 was -11.2 in a Western study. The smaller improvement in the present study could be due to Korean doctors tending to prescribe the drug at a lower dosage, as found in previous studies.

The prevalence of depression is higher among RLS patients than controls. Treating depression in RLS is challenging since some antidepressants reportedly exacerbate or even trigger RLS symptoms. In contrast to a previous study, we found that ropinirole did not improve depression as measured by the BDI-2. This discrepancy could be due to that study using a different (immediate-release) ropinirole formula and a longer treatment duration (12 weeks). Therefore, the antidepressive effects of ropinirole in RLS patients remain unclear, and so future studies should attempt to clarify the antidepressive effects of dopamine agonists such as ropinirole in RLS patients.

Adverse events of ropinirole in the present study were milder in severity and had a lower incidence than those in Western studies. This may be related to our mean dosage of ropinirole being lower than in the other studies. The adverse events were generally consistent with those known for this class of dopamine agonists.

The main weaknesses of our study are that it was not a randomized placebo-controlled trial and there was no long-term follow-up. However, it is significant in being a multicenter clinical trial and finding that Korean RLS patients using ropinirole showed improvement in their QoL, as measured by both the K-RLSQoL and the SF-36. Ropinirole appeared to have a positive impact on QoL in our study, but future studies should evaluate long-term changes in larger populations in order to determine whether QoL improvements are sustained or further enhanced and whether high doses affect QoL to a greater degree than low doses.

In conclusion, this multicenter trial showed that short-term ropinirole is potentially beneficial for the QoL as well as alleviating symptom severity in Korean RLS patients.

Conflicts of Interest

The authors have no financial conflicts of interest.

Acknowledgements

This study was supported by a grant from the Korean Sleep Research Society.
REFERENCES

1. Allen RP, Picciotti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.

2. Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med 2010;11:807-815.

3. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-1292.

4. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164:196-202.

5. Bjorvatn B, Leissner L, Ulfberg J, Gyring J, Karlsborg M, Regeur L, et al. Prevalence, severity and risk factors of restless legs syndrome in two Scandinavian countries. Sleep Med 2005;6:307-312.

6. Cho YW, Shin WC, Yun CH, Hong SB, Kim JH, Allen RP, et al. Epidemiology of restless legs syndrome in Korean adults. Sleep 2008;31:219-223.

7. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237-246.

8. Högl B, Kiechl S, Willeit J, Saletu B, Kessler C, Seppl K, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005;64:1920-1924.

9. Tison F, Crochard A, Léger D, Bouté S, Lainey E, El Hassanie A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005;65:239-246.

10. Allen RP. Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007;120:S13-S21.

11. Abetz L, Allen R, Follet A, Washburn T, Earley C, Kirsch J, et al. Evaluating the quality of life with patients with restless legs syndrome. Clin Ther 2004;26:925-935.

12. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739.

13. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.

14. Trenkwalder C, Hunderer MP, Lledo A, Sweeney J, Polo O, Wetter TC, et al. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 2004;62:1391-1397.

15. Anderssohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Mov Disord 2009;24:129-133.

16. Hornyk M, Trenkwalder C, Kohnen R, Scholz H. Efficacy and safety of dopamine agonists in restless legs syndrome. Sleep Med 2012;13:228-236.

17. Cheer SM, Bang LM, Keating GM. Ropinirole: for the treatment of restless legs syndrome. CNS Drugs 2004;18:747-754; discussion 755-756.

18. Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidwell P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-97.

19. Walters AS, Ondo WG, Dreyfuft T, Granstein R, Lee D, Sethi K, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423.

20. Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM, et al. Ropinirole increases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-914.

21. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY; TREAT RLS US Study Group. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17-27.

22. Cho YW, Lee MY, Yun CH, Shin WC, Hong SB, Kim JH. The reliability and validity of the Korean version of paradigm of questions for epidemiology studies of restless legs syndrome and the Johns Hopkins telephone diagnostic interview form for the restless legs syndrome. J Korean Neurol Assoc 2007;25:494-499.

23. Yang JG, Kim DH, Lee JH, Park KH, Jung KY, Shin WC, et al. The reliability and validity of the Korean versions of the international restless legs scale and the restless legs syndrome quality of life questionnaire. J Korean Neurol Assoc 2010;28:263-269.

24. Han CW, Lee EJ, Iwaya T, Kataoka H, Kobuzuki M. Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea. Tohoku J Exp Med 2004;203:189-194.

25. Solnh Si, Kim DH, Lee MY, Cho YW. The reliability and validity of the Korean version of the Pittsburgh Sleep Quality Index. Sleep Breath 2012;16:803-812.

26. Cho YW, Lee JH, Son HK, Lee SH, Shin C, Johns MW. The reliability and validity of the Korean version of the Epworth Sleepiness scale. Sleep Breath 2011;15:377-384.

27. Oh SM, Min KJ, Park DB. A study on the standardization of the hospital anxiety and depression scale for Koreans: a comparison of normal, depressed and anxious groups. J Korean Neuropsychiatr Assoc 1999;38:289-296.

28. Jo SA, Park MH, Jo I, Ryu SH, Han C. Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population. Int J Geriatr Psychiatry 2007;22:218-223.

29. Kushida C, Martin M, Nikam P, Blaisdell B, Wallenstein G, Ferini-Strambi L, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007;16:617-624.

30. Bogan RK. Ropinirole treatment for restless legs syndrome. Expert Opin Pharmacother 2008;9:611-623.

31. Picciotti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005;28:901-908.

32. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006;7:545-552.

33. Rottach KG, Schaner BM, Kirch MH, Zivotoský AZ, Teufel LM, Gallwitz T, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008;43:70-75.

34. Benes H, Matern W, Peglau I, Dreyfuft T, Bergmann L, Hansen C, et al. Ropinirole improves depressive symptoms and restless leg syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. J Neurol 2011;258:1046-1054.